			-		
Please type a	plus sign (+)	inside	this box	->	+

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

C mpl te if Kn wn					
Application Number	09/957,056				
Filing Date	09/20/2001				
First Named Inventor	Mark L. Tykocinski				
Group Art Unit	1642	ī			
Examiner Name	Alana M. Harris	2			
Attorney Docket Number	285332-00002-2				

1 11	,						Mark E. Tyrodinaki
Į,)				Group Art	Unit	1642
PFICE	/	(use as many s	heets as	necessary)	Examiner	Name	Alana M. Harris
	Sheet	1	of	2	Attorney D	ocket Number	285332-00002-2
~				 		<u> </u>	
				U.S. PA	TENT DOCU	MENTS	285332-00002-2
		U.S. Patent	t Documer	it I		Date of Publication	Pages, Columns, Lines,
Exam Initial	Iminer Cite Kind Code ² Name of Patentee of			Cited Document			
	1		(if knowi)		MM-DD-YYYY	Figures Appear
qu.		5,242,68	87	Tykocinski et al.		09/07/1993	
	В	5,601,82	28	Tykocinski et al.	·	02/11/1997	Where Relevant Passages or Relevant Figures Appear
	С	5,623,05	56	Tykocinski et al.		04/22/1997	
	D	5,698,67	79	Nemazee		12/16/1997	
П	ΙE	5,817,78		Heartlein et al.		10/06/1998	
\mathcal{T}	F	6,027,92	21	Heartlein et al.	_	02/22/2000	
						 	
				<u> </u>			
		· †		-			
	-						
	<u> </u>	<u> </u>					
	1	 				 	
		+					
	+	-		 		 	
	+			-		 	
		+				 	
L.,		1				I	<u> </u>

	FOREIGN PATENT DOCUMENTS									
Examiner Cite Initials* No.1	F	oreign Patent Do		Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant				
	Office ³	Number ⁴	Kind Code ⁵ (if known)	Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T6			
							·			
								Ŧ		
								ĺ		

Examiner	A A Q / Q / A ·	Date	MAINIA ZUODA
Signature	WM Haveus	Considered	May 10, WOG

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Dase type a plus sign (+) inside this box -> +

PTO/SB/088 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

JAN 3 0 2002 nde Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 2 of 2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials No.1 publisher, city and/or country where published. BRUNSCHWIG ET AL., J. Immunolo., 155:5498 (1995) G and MCHUGH ET AL., Proc. Natl. Acad. Sci. USA, 92:8059 (1995) Н MCHUGH ET AL., Cancer Res., 59:2433 (1999) 1 KIM AND PEACOCK, J. Immunol. Methods, 158:57 (1993) J PHILLIPS ET AL., "CD94 and a Novel Associated Protein (94AP) Form a NK Cell Receptor Involved in the Recognition of HLA-A, HLA-B, and HLA-C Allotypes," Immunity, Vol. 5:163-172 (August, 1996) DARLING ET AL., "In Vitro immune modulation by antibodies coupled to tumor cells". Gene Therapy, 4(12):1350-60 (December 1997) LONDO ET AL., "Lateral Diffusion of Antigen Receptors Artificially Incorporated Onto B Lymphocytes," The Journal of Immunology, Vol. 137, 1924-1931, No. 6 (September 15, PEACOCK ET AL., "Biologic Activity of Antigen Receptors Artificially Incorporated Onto B Lymphocytes", The Journal of Immunology, Vol. 137, 1916-1923, No. 6 (September 15, 1986) COLSKY ET AL., "Surrogate Receptor-Mediated Cellular Cytotoxicity", The Journal of Immunology, Vol. 140, 2515-2519, No. 8, (April 15, 1988) COLSKY AND PEACOCK, "Palmitate-derivatized antibodies can function as surrogate receptors for mediating specific cell-cell interactions", Journal of Immunological Methods, Vol. 124, 179-187 (1989) MATZINGER, "A simple assay for DNA fragmentation and cell death", Journal of Q Immunological Methods, Vol. 145, 185-192 (1991)

Examiner Signature	amstaris	Date Considered	Mai	110,2002

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.